Creso Pharma makes technological breakthrough for expansion of human health product line

Special Report: Creso Pharma has unlocked a method to produce hemp oil-free plant based lozenges

Creso Pharma (ASX:CPH) has successfully developed and tested its first hemp oil-free plant-based gum arabicum lozenges.

The technological breakthrough into water-soluble microgranulated hemp plant products will be used to extend the company’s cannaQIX® product line.

Developed over the past nine months with Switzerland’s Domaco Pharma, the new technology allows hemp oil-free production of the gum arabicum lozenges, bringing the full benefit of the natural hemp plant to the consumers.

“The new products contain hemp compounds which are already approved for use in consumer products,’ Dr Miri Halperin Wernli, cofounder and CEO of Creso Pharma, said.

“Importantly, this means that we have an additional path to market for our hemp-based food supplements without the need for regulatory approval, thus increasing our commercial options and expanding the potential territories we can sell the products in.”

The product offers significant regulatory advantages in several countries as the formulation contains hemp compounds which are already approved for use in consumer products, but not hemp”.

“With the achievement of this innovation of the oil-free hemp-based technology Creso successfully addresses the regulatory and market access challenges enabling us to enter additional markets on a global basis,” R&D/commercial director Dr Gian Trepp said.

This will provide the company with a path to market for food supplement products without the need for regulatory approval.

The new products are made from the hemp plant and provide an “entourage effect” in which various compounds work together to strengthen the key benefits such as helping to manage stress and improving well-being.

Creso Pharma plans to distribute the new products globally with different commercial partners in several countries and expects that the products will be ready for launch in Q3 2020.

>> Cannabis stocks guide: Here’s everything you need to know

READ MORE:

Creso hits new milestones: 3 million anibidiol® hemp oil pet doses given, books 700pc sales growth

Creso Pharma’s first Australian import has arrived and sales have already started

Creso extends its global reach with new deal in South Africa

Creso just locked in a New Zealand distribution deal for its CBD products

This story was developed in collaboration with Creso Pharma, a Stockhead advertiser at the time of publishing.

This story does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.